Predictive Effect of Abdominal Fat and Muscle Area Calculated Based on Abdominal CT on Colorectal Cancer Patients
1 other identifier
observational
8,000
1 country
3
Brief Summary
This study aims to create a clinical prediction model. Abdominal fat and muscle area also play an important role in the prediction of surgical outcomes in colorectal cancer. Studies have shown that excess visceral fat and low skeletal muscle mass (sarcopenia) are associated with poorer postoperative outcomes, including a higher risk of postoperative complications and lower survival. Preoperative imaging techniques such as CT, MRI and ultrasound that provide accurate measurements to assess abdominal fat and muscle area can help surgeons develop individualized surgical and rehabilitation plans, improve surgical success, reduce complications and improve long-term patient prognosis. In this study, the investigators expected to construct a prediction model of abdominal fat and muscle area on the short- and long-term outcomes of colorectal cancer patients by calculating the abdominal fat and muscle area in different levels of abdominal CT images, in order to further adjust and guide the treatment plan.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2012
Longer than P75 for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2024
CompletedFirst Submitted
Initial submission to the registry
September 24, 2024
CompletedFirst Posted
Study publicly available on registry
September 26, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2025
CompletedSeptember 27, 2024
September 1, 2024
12 years
September 24, 2024
September 26, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Overall survival
Overall survival was defined as time from date of diagnosis until the date of death from any cause or or loss to follow-up.
From date of diagnosis until the date of death from any cause or or loss to follow-up, whichever came first, assessed up to 60 months.
Secondary Outcomes (1)
Rate of postoperative complications
From date of surgery until the date of first documented postoperative complication, assessed up to 2 months after surgery.
Study Arms (1)
the colorectal cancer group
Abdominal fat and muscle area were calculated based on abdominal CT of colorectal cancer patients.
Interventions
Abdominal fat and muscle area were calculated based on abdominal CT.
Eligibility Criteria
All adult patients diagnosed with colorectal cancer and undergoing radical surgery for colorectal cancer at the study centre.
You may qualify if:
- , Diagnosis of colorectal cancer confirmed by pathology or cytology;
- , aged \>18 years;
- , not received chemotherapy, radiotherapy, targeted therapy or immunotherapy;
- , post-operative pathological stages other than stage IV, or no liver, lung or other organs as confirmed by CT, MRI, B-ultrasound imaging.
- , patients who have pre-operative CT examination data kept in our hospital.
You may not qualify if:
- , Poor quality of preoperative CT images;
- , refusal to participate in this study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (3)
The Affiliated Yongchuan Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400000, China
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400000, China
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400016, China
Related Publications (3)
Sahin MEH, Akbas F, Yardimci AH, Sahin E. The effect of sarcopenia and sarcopenic obesity on survival in gastric cancer. BMC Cancer. 2023 Sep 28;23(1):911. doi: 10.1186/s12885-023-11423-y.
PMID: 37770828BACKGROUNDArulananda S, Segelov E. Sarcopenia and cancer-related inflammation measurements in advanced gastric and junctional cancers-ready for prime time? Ann Oncol. 2022 Jul;33(7):669-671. doi: 10.1016/j.annonc.2022.04.008. Epub 2022 Apr 14. No abstract available.
PMID: 35430371BACKGROUNDXia L, Zhao R, Wan Q, Wu Y, Zhou Y, Wang Y, Cui Y, Shen X, Wu X. Sarcopenia and adverse health-related outcomes: An umbrella review of meta-analyses of observational studies. Cancer Med. 2020 Nov;9(21):7964-7978. doi: 10.1002/cam4.3428. Epub 2020 Sep 13.
PMID: 32924316BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Dong Peng, Ph.D.
First Affiliated Hospital of Chongqing Medical University
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr.
Study Record Dates
First Submitted
September 24, 2024
First Posted
September 26, 2024
Study Start
January 1, 2012
Primary Completion
January 1, 2024
Study Completion
June 1, 2025
Last Updated
September 27, 2024
Record last verified: 2024-09
Data Sharing
- IPD Sharing
- Will not share
IPD is not allowed sharing in this three clinic centers.